Arthritis Monoclonal Antibodies Market Outlook 2025–2034 – Built for Competitive Business Teams

 Unlock 30% off global market reports with code ONLINE30 — get insights on tariff changes, macro trends, and global economic shifts.

 

 What is the expected value of the arthritis monoclonal antibodies market over the forecast period?
 The arthritis monoclonal antibodies market size has grown strongly in recent years. It will grow from $58.09 billion in 2024 to $62.29 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to the rising prevalence of arthritis, increasing awareness of arthritis monoclonal antibodies, expanding the range of approved arthritis monoclonal antibodies, government support for research and development, and increased investment from pharmaceutical companies.
 
 The arthritis monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $83.76 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to combination therapies, expanding indications, patient preference, and increased healthcare spending. Major trends in the forecast period include biosimilars and biobetters, targeted therapies, homecare administration, real-world evidence, cost and access considerations, and advancements in drug delivery.
 
 Download Your Free Sample PDF:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=3449&type=smp
 
 What industry dynamics are acting as key growth drivers for the arthritis monoclonal antibodies market?
 The increasing prevalence of arthritis globally has contributed to the growth of the arthritis monoclonal antibody market. According to the Global RA Network, in 2021, Over 350 million individuals worldwide suffer from arthritis and osteoarthritis is the most common form of arthritis followed by gout, fibromyalgia, and rheumatoid arthritis. For instance, in February 2024, according to Arthritis Australia, an Australia-based charitable not-for-profit organisation, the number of Australians with arthritis will increase from 4.11 million in 2025 to 5.39 million in 2040. The increased prevalence of arthritis is driving the growth of the arthritis monoclonal antibody market.
 
 What are the fastest-growing segments in the arthritis monoclonal antibodies market forecast period?
 The arthritis monoclonal antibodies market covered in this report is segmented –
 
 1) By Drug: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima
 2) By Application: Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Other Applications
 3) By End-Use: Hospitals, Research Institutes, Other End-Users
 
 
 View The Full Market Report:
 https://www.thebusinessresearchcompany.com/report/arthritis-monoclonal-antibodie-global-market-report
 
 What are the most notable trends influencing investment in the arthritis monoclonal antibodies sector?
 The development of therapeutic monoclonal antibody products is becoming an indispensable tool in the development of the arthritis monoclonal antibody market. Monoclonal antibodies are more efficient than small molecules and peptides in the treatment of arthritis. These are target-specific and have good efficiency for disease treatment. These improved treatment options are evident with the launch of a greater number of monoclonal antibody drugs for arthritis.
 
 Which major players hold significant market share in the arthritis monoclonal antibodies sector?
 Major companies operating in the arthritis monoclonal antibodies market include Johnson & Johnson, Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., AbbVie Inc., Amgen Inc., Genentech Inc., GlaxoSmithKline plc., AstraZeneca plc, Bristol Myers Squibb, Eli Lilly and Company, Thermo Fisher Scientific Inc., Sanofi SA, Daiichi Sankyo Company Ltd., Seattle Genetics, Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Corp., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., HanAll Biopharma Co. Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, Regeneron Pharmaceuticals Inc., Samsung Bioepis Co. Ltd.
 
 Which regional segments are forecasted to witness the fastest growth in the arthritis monoclonal antibodies market?
 The countries covered in the arthritis monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
 
 How Can Companies Use The Arthritis Monoclonal Antibodies Market Report to Drive Business Results?
 This report provides actionable insights tailored for business use — not academic analysis. Companies can leverage the data to:
 • Time market entry or expansion using growth forecasts and CAGR trends.
 • Develop competitive products by tracking key technology shifts and user preferences.
 • Tailor regional strategies with in-depth geographic data and local market dynamics.
 • Benchmark and plan partnerships using competitive landscape insights.
 
 Purchase The Report And Get A Swift Delivery:
 https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3449
 
 Need Customized Data On Arthritis Monoclonal Antibodies Market?
 For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
 
 Request Customized Data:
 https://www.thebusinessresearchcompany.com/customise?id=3449&type=smp
 
 About The Business Research Company:
 
 With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
 
 Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
 
 Contact Us:
 
 The Business Research Company
 
 https://thebusinessresearchcompany.com/
 
 Americas +1 310–496-7795
 Europe +44 7882 955267
 Asia & Others +44 7882 955267 & +91 8897263534
 Email us at info@tbrc.info
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company